Therapeutic uses of melatonin and melatonin derivatives: A patent review (2012 - 2014)

Expert Opinion on Therapeutic Patents

Volumn 25, Issue 4, 2015, Pages 425-441

  Rivara, Silvia ^a   Pala, Daniele ^a   Bedini, Annalida ^b   Spadoni, Gilberto ^b  

^a UNIVERSITY OF PARMA   (Italy)

^b UNIVERSITY OF URBINO   (Italy)

Author keywords

Agomelatine; Antioxidant activity; Controlled release formulation; Melatonin; MT1 receptor; MT2 receptor; Radical scavenger; Ramelteon; Tasimelteon; TIK 301

Indexed keywords

AGOMELATINE; MELATONIN; MELATONIN DERIVATIVE; RAMELTEON; TACRINE DERIVATIVE; TAMOXIFEN; TASIMELTEON; ANTIOXIDANT; HYPNOTIC SEDATIVE AGENT; LIGAND;

ALCOHOL INTOXICATION; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT ACTIVITY; BILE DUCT CARCINOMA; BREAST CANCER; CIRCADIAN RHYTHM SLEEP DISORDER; DEPRESSION; DIABETES MELLITUS; DRUG MECHANISM; FIBROMYALGIA; FOOD INTAKE; GASTROINTESTINAL ABSORPTION; GASTROINTESTINAL DISEASE; HEAD INJURY; HUMAN; HYPERTENSION; IMMUNE SYSTEM; INSOMNIA; IRRITABLE COLON; MIGRAINE; NEOPLASM; NEUROPATHIC PAIN; NEUROPROTECTION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; ORAL MUCOSITIS; PAIN; PARKINSON DISEASE; PATENT; REPRODUCTION; REVIEW; SLEEP DISORDER; STEM CELL TRANSPLANTATION; URINE INCONTINENCE; ANIMAL; BIOAVAILABILITY; CIRCADIAN RHYTHM; DIETARY SUPPLEMENT; HALF LIFE TIME; METABOLISM; PHYSIOLOGY; TISSUE DISTRIBUTION;

ANIMALS; ANTIOXIDANTS; BIOLOGICAL AVAILABILITY; CIRCADIAN RHYTHM; DIETARY SUPPLEMENTS; HALF-LIFE; HUMANS; HYPNOTICS AND SEDATIVES; LIGANDS; MELATONIN; PATENTS AS TOPIC; TISSUE DISTRIBUTION;

EID: 84924981060     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.1001739     Document Type: Review

References (110)

1. Lerner AB, Case JD, Takahashi Y, et al. Isolation of melatonin: the pineal gland factor that lightens melanocytes. J Am Chem Soc 1958;80:2587
2. Acuña-Castroviejo D, Escames G, Venegas C, et al. Extrapineal melatonin: sources, regulation, and potential functions. Cell Mol Life Sci 2014;71:2997-3025
3. Pandi-Perumal SR, Trakht I, Srinivasan V, et al. Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol 2008;85:335-53
4. Carpentieri A, Díáz de Barboza G, Areco V, et al. New perspectives in melatonin uses. Pharmacol Res 2012;65:437-44
5. Sanchez-Barcelo E, Mediavilla MD, Tan DX, Reiter RJ. Clinical uses of melatonin: evaluation of human trials. Curr Med Chem 2010;17:2070-95
6. Dubocovich ML, Delagrange P, Krause DN, et al. International Union of basic and clinical pharmacology. LXXV. Nomenclature, classification and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev 2010;62:343-80
7. Slominski RM, Reiter RJ, Schlabritz-Loutsevich N, et al. Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol 2012;351:152-66
8. Hardeland R. Melatonin: signaling mechanisms of a pleiotropic agent. Biofactors 2009;35:183-92
9. Reiter RJ, Tan DX, Rosales-Corral S, Manchester LC. The universal nature, unequal distribution and antioxidant functions of melatonin and its derivatives. Mini Rev Med Chem 2013;13:373-84
10. Lemoine P, Zisapel N. Prolonged-release formulation of melatonin (Circadin) for the treatment of insomnia. Expert Opin Pharmacother 2012;13:895-905
11. Zlotos R, Jockers R, Cecon E, et al. MT1 and MT2 melatonin receptors: ligands, oligomers and therapeutic potential. J Med Chem 2014;57:3161-85
12. Leclerc V, Ettaoussi M, Rami M, et al. Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3. Eur J Med Chem 2011;46:1622-9
13. Spadoni G, Bedini A, Rivara S, Mor M. Melatonin receptor agonists: new options for insomnia and depression treatment. CNS Neurosci Ther 2011;17:733-41
14. Zemlan FP, Mulchahey JJ, Scharf MB, et al. The efficacy and safety of the melatonin agonist beta-methyl-6-chloromelatonin in primary insomnia: a randomized, placebo-controlled, crossover clinical trial. J Clin Psychiatry 2005;66:384-90
15. Schutte-Rodin S, Broch L, Buysse D, et al. Clinical guideline for the evaluation and management of chronic insomnia in adults. J Clin Sleep Med 2008;4:487-504
16. Ferguson SA, Rajaratnam SMW, Dawson D. Melatonin agonists and insomnia. Expert Rev Neurother 2010;10:305-18
17. Requis Pharmaceutical, Inc. Antihistamines combined with dietary supplements for improved health. US0199417; 2014
18. Casal Y, Garzov RE. Drug composition for the treatment of insomnia. WO109695; 2012
19. Nestec SA. Methods and compositions useful for promoting sleep in animals. US0273176; 2013
20. Nestec SA. Compositions and methods for enhancing cognitive and related functions in animals. US0171303; 2012
21. Tianjin Tiens Biolog Dev Co., Tianjin Tiens Life Sources Co Ltd; Tiens Group Co Ltd. Medlar and tuckahoe composition and preparation method thereof. CN102552536; 2012
22. Guangzhou Gonghe Medicine Tecnology Co Ltd; Guangzhou Xiangkun Medicine Tecnology Co Ltd. Anti-insomnia composition, application of composition, multi-phase pulse immediate-release preparation prepared by use of composition and preparation method of preparation. CN103550775; 2014
23. Dongguan Zhaoyan Biotechnology Co Ltd. Nutritional health-care product for improving agrypnia. CN102688416; 2012
24. Keller RM. Formulation and method to induce a deep state of relaxation. WO166246; 2013
25. Takeda Pharmaceutical Co. Ltd. Tricyclic compound and pharmaceutical use thereof. US8552037; 2013
26. Koike T, Takai T, Hoashi Y, et al. Synthesis of a novel series of tricyclic dihydrofuran derivatives: discovery of 8,9-dihydrofuro[3,2-c]pyrazolo[1,5-a] pyridines as melatonin receptor (MT1/ MT2) ligands. J Med Chem 2011;54:4207-18
27. Vanda Pharmaceuticals, Inc. Use of melatonin agonist for the treatment of sleep disorders including primary insomnia. US0136050; 2012
28. Vanda Pharmaceuticals, Inc. Treatment of circadian rhythm disorders. US8785492; 2014
29. Obshchestvo S Ogranichennoj Otvetstvennost'ju "Ehr Ehnd Di Farma". Pharmaceutical composition for prevention and treatment of depressions. RU2011109649; 2012
30. Parshin AN, Gilod VM. Method of treating adaptation disorders in patients with risk of suicidality. RU2506073; 2014
31. Joshi N, Biswas J, Nath C, Singh S. Promising role of melatonin as neuroprotectant in neurodegenerative pathology. Mol Neurobiol 2014. doi: 10.1007/s12035-014-8865-8
32. Polimeni G, Esposito E, Bevelacqua V, et al. Role of melatonin supplementation in neurodegenerative disorders. Front Biosci (Landmark ed) 2014;19:429-46
33. Bennett M, Peller G. Compositions and methods for treating traumatic brain injury. CA2799127. 2014
34. Centrum Medyczne Ksztalcenia Podyplomowego - Uniwersytet Warszawski. Novel hybrid cholinesterase inhibitors. US8841453; 2014
35. Regents of University of Minnesota. Ischemia/reperfusion protection compositions and methods of using. US8728532; 2014
36. Jacobson KA. Adenosine A3 receptors: novel ligands and paradoxical effects. Trends Pharmacol Sci 1998;19:184-91
37. Korea University Research and Business Foundation. A composition comprising the combination of adenosine derivative and melatonin for treating and preventing neuro-degenerative disease. KR0103927; 2013
38. Morozova MA, Beniashvili AG, Zapolskii ME. Combination for the prophylaxis treatment of behavioural, mental, and cognitive disorders. WO054965; 2014
39. Jeong JK, Moon MH, Lee YJ, et al. Melatonin-induced autophagy protects against human prion protein-mediated neurotoxicity. J Pineal Res 2012;53:138-46
40. Industrial Cooperation Foundation Chonbuk National University. Novel uses of melatonin. WO109016; 2013
41. Industry-Academic Cooperation Foundation, Yonsei University. Pharmaceutical composition for preventing or treating protein aggregate-inducing diseases. KR0014801; 2014
42. Kanno H, Ozawa H, Sekiguchi A, et al. The role of mTOR signaling pathway in spinal cord injury. Cell Cycle 2012;11:3175-9
43. Nestec SA. Methods for reducing neurodegeneration. US0113949; 2014
44. Wilhelmsen M, Amirian I, Reiter RJ, et al. Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies. J Pineal Res 2011;51:270-7
45. Cecype Services S. DE R.L. DE C.V. Pharmaceutical composition comprising a combination of a non-steroidal anti-inflammatory agent, an adjuvant and an antineuritic analgesic, having an antinociceptive effect. WO098552; 2014
46. Bizzarri M, Proietti S, Cucina A, Reiter RJ. Molecular mechanisms of the pro-apoptotic actions of melatonin in cancer: a review. Expert Opin Ther Targets 2013;17:1483-96
47. Clinical trial identifier NCT01965522 Anti-proliferative effects of vitamin D and melatonin in breast cancer. Available from: https://clinicaltrials.gov/ct2/show/NCT01965522
48. Clinical trial identifier NCT00668707 Adjuvant melatonin for prevention of lung cancer recurrence and mortality. Available from: https://clinicaltrials.gov/ct2/show/NCT00668707
49. Ekmekcioglu C. Expression and putative functions of melatonin receptors in malignant cells and tissues. Wien Med Wochenschr 2014;164:472-8
50. Grant SG, Melan MA, Latimer JJ, Witt-Enderby PA. Melatonin and breast cancer: cellular mechanisms, clinical studies and future perspectives. Expert Rev Mol Med 2009;11:e5
51. Sanchez-Barcelo EJ, Mediavilla MD, Alonso-Gonzales C, Reiter RJ. Melatonin uses in oncology: breast cancer prevention and reduction of the side effects of chemotherapy and radiation. Expert Opin Investig Drugs 2012;21:819-31 Review on melatonin potential in prevention, treatment and protection from chemotherapy side-effects.
52. Duquesne University of the Holy Spirit. Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer. US8618083; 2013
53. Duquesne University of the Holy Spirit. Anti-cancer tamoxifen-melatonin hybrid ligand. US8785501; 2014
54. Scott & White Healthcare. Melatonin-based treatment and diagnosis of bile duct disease. US0079680; 2014
55. Han Y, Demorrow S, Invernizzi P, et al. Melatonin exerts by an autocrine loop antiproliferative effects in cholangiocarcinoma: its synthesis is reduced favoring cholangiocarcinoma growth. Am J Physiol Gastrointest Liver Physiol 2011;301:G623-33
56. Clinical trial identifier NCT01557478 Melatonin as adjuvant therapy in breast cancer patients. Available from: https://clinicaltrials.gov/ct2/show/NCT01557478
57. Universidad de Granada. Use of melatonin for treating and/or preventing mucositis. US0243384; 2014
58. Ruiqiong R. Vulcanized aspartic acid modified melatonin derivative and application thereof. CN102816103; 2014
59. Galano A, Tan DX, Reiter RJ. Melatonin as a natural ally against oxidative stress: a physicochemical examination. J Pineal Res 2011;51:1-16
60. Luchetti F, Canonico B, Betti M. Melatonin signaling and cell protection function. FASEB J 2010;24:3603-24
61. Carrillo-Vico A, Lardone PJ, Alvarez-Sánchez N, et al. Melatonin: buffering the immune system. Int J Mol Sci 2013;14:8638-83
62. University of Sunderland. Melatonin derivatives and their use as antioxidants. US8258173; 2012
63. Iasomai AB. New combination comprising N-acetyl-L-cysteine and its use. WO130609; 2012
64. Nutri-Fit GMBH. Melatonin and its use in preventing postoperative complications. US0249198; 2014
65. Yang Y, Sun Y, Yi W, et al. A review of melatonin as a suitable antioxidant against myocardial ischemia-reperfusion injury and clinical heart diseases. J Pineal Res 2014;57:357-66
66. Tianjin Pacific Pharmaceutical. Traditional Chinese medicine composition used for treating low immunity in middle-aged and elderly people. CN102872294; 2013
67. Slominski AT, Kleszczynski K, Semak I, et al. Local melatoninergic system as the protector of skin integrity. Int J Mol Sci 2014;15:17705-32
68. Universidad de Granada. Composition comprising melatonin or its derivatives with coenzyme Q10 and use thereof against ageing of the skin. WO083227; 2014
69. Mavi Sud s.r.l. Melatonin and immunostimulating substance-based compositions. US8802117; 2014
70. Novaera s.r.l. Melatonin and an antimicrobial or antibacterial agent for the treatment of acne. US0199413; 2014
71. Suzhou Guli Biotechnology Co. Skin whitening cream. CN102860978; 2013
72. Luchetti F, Canonico B, Bartolini D, et al. Melatonin regulates mesenchymal stem cell differentiation: a review. J Pineal Res 2014;56:382-97
73. Maria S, Witt-Enderby PA. Melatonin effects on bone: potential use for the prevention and treatment for osteopenia, osteoporosis, and periodontal disease and for use in bone-grafting procedures. J Pineal Res 2014;56:115-25 Comprehensive review on the mechanisms sustaining melatonin effects on bone.
74. Duquesne University of the Holy Spirit. Enhanced bone healing. US0029960; 2013
75. Riukowski JL. Formulations and methods for recovery from dental surgery. EP2711012; 2014
76. Sun Yat-Sen University. Application of melatonin synergistic extracellular matrix biomaterial to preparation of medicament for promoting osteoblast differentiation of mesenchymal stem cells. CN103736150; 2014
77. Sun Yat-Sen University. Application of melatonin in preparation of drugs for promoting mesenchymal stem cell chondrogenic differentiation. CN103494808; 2014
78. Medical College of Georgia, University of South Florida. Method of diseaseinduced and receptor-mediated stem cell neuroprotection. US0009271; 2012
79. Brzozowska I, Strzalka M, Drozdowicz D, et al. Mechanisms of esophageal protection, gastroprotection and ulcer healing by melatonin. implications for the therapeutic use of melatonin in gastroesophageal reflux disease (GERD) and peptic ulcer disease. Curr Pharm Des 2014;20:4807-15
80. De Souza Pereira R. Method using a dietary supplement for healing or regressing symptoms of gastroesophageal reflux disease, gastritis and ulcers. US0090305; 2013
81. De Souza Pereira R. Regression of gastroesophageal reflux disease symptoms using dietary supplementation with melatonin, vitamins and aminoacids: comparison with omeprazole. J Pineal Res 2006;41:195-200
82. Obshchestvo S Ogranichennoj Otvetstvennost'ju "Ehr Ehnd Di Farma". Pharmaceutical composition for gastric and/or duodenal ulcer. RU2010129474; 2012
83. Celinski K, Konturek SJ, Konturek PC, et al. Melatonin or L-tryptophan accelerates healing of gastroduodenal ulcers in patients treated with omeprazole. J Pineal Res 2011;50:389-94
84. Clinical trial identifier NCT01566474 Melatonin associated to acid inhibition for chemoprevention in barret esophagus: a pilot study. Available from: https://clinicaltrials.gov/ct2/show/NCT01566474
85. Nestec SA. Methods for increasing absorption of peptides, peptidomimetics and other gastrointestinal transport protein substrates. US8492331; 2013
86. Navarro-Alarcón M, Ruiz-Ojeda FJ, Blanca-Herrera RM, et al. Melatonin and metabolic regulation: a review. Food Funct 2014;5:2806-32
87. Korea Food Research Institute. Composition of food components for appetite control comprising specific compounds as effective component. KR0046967; 2012
88. Korea Food Research Institute. Composition for promoting leptin secretion comprising specific compounds as effective component. KR0010192; 2013
89. Pechanova O, Paulis L, Simko F. Peripheral and central effects of melatonin on blood pressure regulation. Int J Mol Sci 2014;15:17920-37
90. Grossman E, Laudon M, Zisapel N. Effect of melatonin on nocturnal blood pressure: meta-analysis of randomized controlled trials. Vasc Health Risk Manag 2011;7:577-84
91. Neurim Pharma 1991. Method and formulation for treating resistance to antihypertensives and related conditions. US8075914; 2011
92. Obshchestvo S Ogranichennoj Otvetstvennost'ju "Ehr Ehnd Di Farma". Pharmaceutical composition for treating and/or preventing arterial hypertension. RU2010129473; 2012
93. Peschke E. Melatonin, endocrine pancreas and diabetes. J Pineal Res 2008;44:26-40
94. Kemp DM, Ubeda M, Habener JF. Identification and functional characterization of melatonin Mel 1a receptors in pancreatic-cells: potential role in incretin-mediated cell function by sensitization of cAMP signaling. Mol Cell Endocrinol 2002;191:157-66
95. Takahashi JS, Kay SA. Compositions and methods for diabetes treatment. US0232003; 2012
96. Wang F, Tian X, Zhang L, et al. Melatonin promotes the in vitro development of pronuclear embryos and increases the efficiency of blastocyst implantation in murine. J Pineal Res 2013;55:267-74
97. Tamura H, Takasaki A, Miwa I, et al. Oxidative stress impairs oocyte quality and melatonin protects oocytes from free radical damage and improves fertilization rate. J Pineal Res 2008;44:280-7
98. Maxia N. Use of N-acetyl-5-methoxytriptamine or analogs thereof, for promoting the mechanism of implantation of the embryo and related compositions and culture media. WO178587; 2013
99. Olcese J, Beesley S. Clinical significance of melatonin receptors in the human myometrium. Fertil Steril 2014;102:329-35
100. The Florida State University Research Foundation, Inc. Methods of treating pre-term labor. US0088057; 2014
101. Astellas Pharma, Inc. Pharmaceutical composition for treating or preventing stress urinary incontinence or mixed incontinence, and method for screening compounds to be included in said pharmaceutical composition. WO010603; 2014
102. Gomez-Pinilla PJ, Gomez MF, Swärd K, et al. Melatonin restores impaired contractility in aged guinea pig urinary bladder. J Pineal Res 2008;44:416-25
103. Rassoulian D. Use of melatonin to treat acute alcohol intoxication. EP2570126; 2014
104. Mor M, Rivara S, Pala D, et al. Recent advances in the development of melatonin MT1 and MT2 receptor agonists. Expert Opin Ther Patents 2010;20:1059-77
105. Hardeland R, Cardinali DP, Srinivasan V, et al. Melatonin-A pleiotropic orchestrating regulator molecule. Prog Neurobiol 2011;93:350-84
106. Rodríguez-Franco MI, Fernández-Bachiller MI, Pérez C, et al. Novel tacrine-melatonin hybrids as dualacting drugs for Alzheimer disease, with improved acetylcholinesterase inhibitory and antioxidant properties. J Med Chem 2006;49:459-62
107. López-Iglesias B, Pérez C, Morales-Garcíá JA, et al. New melatonin-N,N-dibenzyl(N-methyl)amine hybrids: potent neurogenic agents with antioxidant, cholinergic, and neuroprotective properties as innovative drugs for Alzheimer's disease. J Med Chem 2014;57:3773-85
108. Fernández-Bachiller MI, Pérez C, Campillo NE, et al. Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties. ChemMedChem 2009;4:828-41
109. Ochoa-Sanchez R, Comai S, Lacoste B, et al. Promotion of non-rapid eye movement sleep and activation of reticular thalamic neurons by a novel MT2 melatonin receptor ligand. J Neurosci 2011;31:18439-52
110. Noseda AC, Rodrigues LS, Targa AD, et al. Putative role of monoamines in the antidepressant-like mechanism induced by striatal MT2 blockade. Behav Brain Res 2014;275:136-45